Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

FDA Probing Adverse Events Linked To Ariad Pharmaceuticals Inc's Cancer Drug-Reuters

Friday, 11 Oct 2013 10:49am EDT 

Reuters reported that the U.S. Food and Drug Administration said it is investigating an increasing number of reports of serious and life-threatening adverse events in patients taking Ariad Pharmaceuticals Inc's leukemia drug, Iclusig. In a safety notice posted on its website, the regulator advised patients taking Iclusig to seek immediate medical attention if they experience symptoms suggesting a heart attack. The notice comes after Ariad disclosed on October 09, 2013 that the FDA asked the Company to stop enrolling patients in clinical trials of Iclusig. The agency had identified a number of patients who had experienced blood clots and heart damage after taking the drug. Iclusig was approved by the FDA in December 2012 to treat adults with two types of blood cancers - chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. The drug's label contains information about the risks of blood clots. The Company is testing the drug in seven mid-stage studies for lung cancer, thyroid cancer and another form of blood cancer. The FDA said that the most recent clinical trial data Ariad had submitted showed at least 20% of patients developed blood clots or narrowing of blood vessels. The agency also said it recently received reports showing that patients treated with Iclusig experienced serious eye problems, including decreased vision and clots in blood vessels of the eye. 

Company Quote

0.52 +7.98%
12:49pm EST